Mechanistic analysis of Acalabrutinib (Calquence)

June 19, 2020COVID-19, Vizit Graphs

Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More

Targeting the RAS system against COVID-19

June 19, 2020COVID-19, Vizit Graphs

There is growing amount of evidence to suggest the use of pharmaceuticals that target the Renin-Angiotensin System (e.g. angiotensin 1-7, ARBs and ACE inhibitors) may be beneficial in the treatment of COVID-19. This graph shows the interconnections among these classes of drugs, and SARS-CoV-2 via key genes implicated in this pathway. mediated. Explore the live … Read More

Administration of vitamin D could help fight COVID-19

June 19, 2020COVID-19, Vizit Graphs

Vitamin D supplementation has been shown to protect against SARS-COV-2 infection, and could be particularly helpful for patients that exhibit shortage of vitamin D (e.g. seniors, immunocompromised patients) leading to complications such as cardiovascular comorbidities. This graph explains the mechanism of action of vitamin D in COVID-19 via key genes implicated. Explore the live graph.

Mechanistic analysis of Azithromycin

June 19, 2020COVID-19, Vizit Graphs

Azithromycin is being tested in COVID-19 patients. Although it is a potent antibiotic, in the COVID-19 setting, it likely acts as an anti-inflammatory agent. Its exact MoA in the disease, however, remains to be elucidated. Explore the live graph.